Utilization and Expenditures Trends of Phytopharmaceuticals in Indonesia: Strategic Approaches to Boost Herbal Product Competitiveness
DOI:
https://doi.org/10.35451/3kbr5f29Keywords:
Phytopharmaceutical, Traditional Medicine, Medicine Expenditure, Cost Medicine, CompetitivenessAbstract
Traditional medicine in Indonesia, rooted in local wisdom, is recognized nationally and internationally to support public health preventively, promotively, and curatively, backed by government commitments through regulations such as jamu certification and the Germas program, as well as the abundant biodiversity of thousands of medicinal plant species serving as raw materials for the significant national traditional medicine industry, with ongoing scientification efforts to ensure safety and efficacy. This study aimed to identify trends in the utilization and expenditure of phytopharmaceutical drugs and to provide alternative strategies for enhancing the competitiveness of phytopharmaceuticals as traditional medicine. A cross-sectional study with a quantitative descriptive approach utilized secondary data on domestic phytopharmaceutical drug expenditures from 2023–2024 sourced from the Ministry of Health's LKPP e-purchasing system, which was processed using Microsoft Excel and analyzed descriptively for frequency distribution, percentages, patterns, and trends. Total phytopharmaceutical expenditure reaches Rp25.94 billion, with an increase from Rp11.08 billion in 2023 to Rp14.86 billion in 2024; provinces with the highest spending include Central Java (Rp3.88 billion), followed by West Java (Rp3.02 billion) and East Java (Rp2.38 billion), which contribute more than one-third of the national total, while immunomodulator products like Stimuno dominate with Rp15.01 billion, but utilization for chronic diseases remains low, such as hypertension (Tensigard: Rp1.08 billion) and diabetes (Diabadex: Rp0.295 billion). This study concludes that although phytopharmaceutical expenditure and utilization show positive trends, their utilization is not yet optimal due to limitations in integration into the National Health Insurance, regional distribution disparities, high research costs, as well as low promotion and acceptance among healthcare professionals and the public.
Downloads
References
[1] Badan Pengawas Obat dan Makanan. (2024). Data pendaftaran fitofarmaka hingga September 2024. Jakarta: BPOM.
[2] Badan Pengawas Obat dan Makanan. (2019). Analisis Ketergantungan Indonesia Terhadap Impor Bahan Baku Obat. Jakarta: BPOM
[3] Fitriana, N. S. R. (2020). Penggunaan Obat Herbal di Masyarakat Jawa: Studi Etnofarmakologi. Jurnal Farmasi Indonesia, 12(2), 45–60.
[4] Herlina, L., Utami, D., & Rahmadani, T. (2022). Pemetaan potensi dan persebaran fitofarmaka di Indonesia. Jurnal Kefarmasian Indonesia, 12(2), 121–137.
[5] Kebijakan Pembangunan, B., Kementerian, K., & Ri, K. (2023). SURVEY KESEHATAN INDONESIA (SKI) DALAM ANGKA.
[6] kementerian kesehatan. (2024). LAPORAN KINERJA DIREKTORAT KETAHANAN FARMASI DAN ALKES TAHUN 2024.
[7] Rifana S, R. (2005). STRATEGI BERSAING FITOFARMAKA MENGHADAPI OBAT MODERN. Tesis : Universitas Indonesia (2005)
[8] Kementerian Kesehatan Republik Indonesia (2022), Buku Formularium Fitofarmaka, Jakarta : Ditjen Kefarmasian dan Alkes, Kemenkes RI.
[9] Kementerian Kesehatan Republik Indonesia (2024), Laporan Kinerja Direktorat Ketahanan Kefarmasian dan Alat Kesehatan Tahun 2024. Jakarta : Kemenkes RI
[10] Kementerian Kesehatan RI. 2020. Peraturan Menteri Kesehatan Republik Indonesia Nomor 85 Tahun tentang Petunjuk Operasional Penggunaan Dana Alokasi Khusus Fisik Bidang Kesehatan Tahun Anggaran 2020. Jakarta: Kementerian Kesehatan RI.
[11] Kementerian Kesehatan RI. 2020. Peraturan Menteri Kesehatan Republik Indonesia Nomor 86 Tahun tentang Petunjuk Teknis Penggunaan Dana Alokasi Khusus Nonfisik Bidang Kesehatan Tahun Anggaran 2020. Jakarta: Kementerian Kesehatan RI.
[12] Kementerian Kesehatan RI. 2020. Peraturan Menteri Kesehatan Nomor 21 Tahun 2020 Tentang Rencana Strategis Kementerian Kesehatan Indonesia Tahun 2020-2024.
[13] Kementerian Kesehatan Republik Indonesia. (2023). Profil Kesehatan Indonesia 2023. Jakarta: Kemenkes RI.
[14] Kementerian Kesehatan Republik Indonesia. (2024). Profil Kesehatan Indonesia 2024. Jakarta: Kemenkes RI.
[15] Kementerian Kesehatan RI, 2018. Laporan Nasional RISKESDAS 2018, Jakarta : Badan Penelitian dan Pengembangan Kesehatan.
[16] Portal satu data BPOM : https://satudata.pom.go.id/datasets/29-jumlah-produk-obat-tradisional-berdasarkan-kategori?lang=id&tabs=tabs2
[17] Peraturan Pemerintah (PP) Nomor 103 Tahun 2014 tentang Pelayanan Kesehatan Tradisional, Jakarta : 2014
[18] Rachmawati, I., Prabowo, S., & Wibisono, A. (2021). Potensi dan tantangan pengembangan fitofarmaka di Indonesia. Media Penelitian dan Pengembangan Kesehatan,31(4),201–214.
[19] Survei Kesehatan Indonesia. (2023). Laporan pemanfaatan upaya kesehatan tradisional. Jakarta: Kemenkes RI.
[20] Suharyanto, B. (2020). Distribusi dan aksesibilitas obat tradisional berbasis tanaman obat di kawasan timur Indonesia. Jurnal Farmasi Indonesia, 10(1), 45–57.
[21] Yuliana, E., & Handoko, T. (2019). Fitofarmaka sebagai pilar ketahanan kesehatan nasional. Jurnal Sains dan Kesehatan, 5(2), 87–99.
[22] Fred, R. David., Forest, R. David (2017). Manajemen Strategik : Suatu Pendekatan Keunggulan Bersaing. Penerbit Salemba Empat, Edisi 15, Cetakan kedua (2017)
[23] Sembiring, E.N., & Damayanti, S. (2023), Pendampingan Uji Klinik Obat Bahan Alam Pada Masa Pandemi Covid-19 Dalam Upaya Hilirisasi Penelitian Menjadi Fitofarmaka, Jurnal Inovasi Ilmu Kesehatan, Vol.2(4).
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Diara Oktania Oktania, Pujiyanto, Yeni, Dumilah Ayuningtyas
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright in each article is the property of the Author.
